查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1941471

疫苗佐剂市场规模、份额和趋势分析报告：按类型、应用、剂量、地区和细分市场划分，预测期为2026-2033年

Vaccine Adjuvants Market Size, Share & Trends Analysis Report By Type, By Application, By Administration, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

疫苗佐剂市场概述

2025年全球疫苗佐剂市场规模估计为39.4亿美元，预计2033年将达到59.6亿美元。

预计从 2026 年到 2033 年，该市场将以 5.60% 的复合年增长率成长。推动该市场成长的因素包括：对有效疫苗的需求不断增长，以对抗新兴和再发感染疾病；以及癌症等慢性疾病的日益普及。

人们越来越认识到佐剂在增强免疫反应的效力、持续时间和广度方面的作用，这推动了佐剂在预防性和治疗性疫苗中的应用。免疫学和分子生物学的进步促成了新一代佐剂的开发，例如皂素佐剂和Toll样受体（TLR）促效剂，这些佐剂能够选择性地靶向免疫通路，并具有更高的安全性和有效性。这些创新满足了疫苗的迫切需求，即在降低抗原剂量的同时诱导强效的免疫反应，从而提高成本效益和扩充性。例如，Springer Nature于2025年8月在《药物化学研究》（Medicinal Chemistry Research，第34卷，第1817-1832页）上发表的一篇综述指出，广泛研究的皂素佐剂QS-21由约65%的QS-21-Api和35%的甲苯二构体组成。作者报告了该化合物生物合成的成功阐明，并比较了半合成法所得产率。具体而言，利用基因改造酵母生产的该化合物的重量比约为0.0012%，而天然来源的该化合物的重量比约为0.0032%，这凸显了其在增强抗原特异性抗体和细胞免疫反应中的作用。

此外，各国政府、非政府组织和製药公司不断增加对疫苗研发的投资，也推动了市场成长。在全球范围内，尤其是在中低收入国家，扩大先进佐剂疫苗使用的努力发挥核心作用。例如，2024年6月，全球疫苗免疫联盟（Gavi）核准了其新的五年策略－Gavi 6.0。该策略承诺在2026年至2030年间，支持为超过5亿名儿童和青少年接种疫苗，预防800万至900万人死亡（其中150万人死于人类乳突病毒(HPV)疫苗），并扩大20多种疾病疫苗的覆盖范围。该策略尤其关注登革热等气候敏感型疾病，以及一种计划在战略週期结束前推出的新型结核病疫苗。这些努力，加上在 COVID-19 和其他感染疾病爆发后加强的疫情防范措施，进一步强调了快速开发和部署佐剂疫苗的必要性。

市场也受益于有利的监管支持，包括加快核准流程和优先资助关键疫苗技术。然而，高昂的研发成本、严格的监管要求以及广泛的临床检验需求等挑战仍然是主要障碍。儘管有这些限制，但基于佐剂的疫苗开发平臺的不断扩展，以及全球对疫苗接种在公共卫生中作用的认识不断提高，预计将推动疫苗佐剂产业在预测期内持续成长。

目录

第一章调查方法和范围

第二章执行摘要

3. 疫苗佐剂市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关及配套市场展望
  • 绘製渗透率和成长前景图
  • 市场动态
  • 疫苗佐剂市场分析工具
    • 产业分析：波特五力模型
    • PESTEL 分析

第四章 疫苗佐剂：按类型分類的估算与趋势分析

  • 疫苗佐剂市场：主要结论
  • 疫苗佐剂市场：趋势分析与市占率分析（2025 年和 2033 年）
  • 病原
  • 佐剂乳剂
  • 颗粒物
  • 组合
  • 其他的

第五章 疫苗佐剂：依使用情况进行的估算与趋势分析

  • 疫苗佐剂市场：主要结论
  • 疫苗佐剂市场：趋势分析与市占率分析（2025 年和 2033 年）
  • 感染疾病
  • 癌症
  • 其他的

第六章 疫苗佐剂：按剂量进行的估算与趋势分析

  • 疫苗佐剂市场：主要结论
  • 疫苗佐剂市场：趋势分析与市占率分析（2025 年和 2033 年）
  • 口服
  • 皮内给药
  • 鼻腔
  • 肌肉内注射
  • 其他的

第七章 疫苗佐剂市场：区域预测与趋势分析

  • 区域展望
  • 疫苗佐剂市场区域分析：要点
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 对主要市场参与企业近期趋势和影响的分析
  • 市场参与企业分类
    • GlaxoSmithKline plc
    • Novartis/CSL Limited
    • Agenus Inc
    • Adjuvance Technologies, Inc
    • Novavax Inc.
    • SPI Pharma
    • Invivogen
    • Avanti Polar Lipids
    • Brentagg
Product Code: GVR-1-68038-612-7

Vaccine Adjuvants Market Summary

The global vaccine adjuvants market size was estimated at USD 3.94 billion in 2025 and is projected to reach USD 5.96 billion by 2033, growing at a CAGR of 5.60% from 2026 to 2033. The growth of the market is driven by the increasing demand for effective vaccines to combat emerging and re-emerging infectious diseases, as well as the rising prevalence of chronic conditions such as cancer.

The growing recognition of adjuvants' role in enhancing the efficacy, durability, and breadth of immune responses is propelling their adoption across both prophylactic and therapeutic vaccines. Advancements in immunology and molecular biology have enabled the development of next-generation adjuvants, including saponin-based adjuvants and toll-like receptor (TLR) agonists, which selectively target immune pathways and deliver improved safety and efficacy profiles. These innovations address the unmet need for vaccines capable of eliciting strong immune responses with reduced antigen doses, improving cost efficiency and scalability. For instance, in August 2025, Springer Nature published a review in Medicinal Chemistry Research (Volume 34, pages 1817-1832) highlighting that the widely studied saponin adjuvant QS-21 consists of approximately 65 percent QS-21-Api and 35 percent QS-21-Xyl isomers and has been incorporated into licensed vaccines such as Shingrix, Mosquirix, and Arexvy, with the authors reporting successful biosynthetic elucidation and comparing semi-synthetic yields, including engineered yeast production at roughly 0.0012 percent weight-by-weight versus about 0.0032 percent from natural sources, underscoring its role in enhancing antigen-specific antibody and cellular immune responses.

In addition, rising investments in vaccine research and development by governments, non-governmental organizations, and pharmaceutical companies are accelerating market growth. Global initiatives are playing a central role in expanding access to advanced adjuvanted vaccines, particularly in low- and middle-income countries. For instance, in June 2024, Gavi, the Vaccine Alliance approved its new five-year strategy, Gavi 6.0, committing to support countries in vaccinating more than 500 million additional children and adolescents, projecting the prevention of 8-9 million deaths, including 1.5 million through HPV vaccination, and expanding access to vaccines targeting 20+ diseases during the 2026-2030 period, with an added focus on climate-sensitive diseases such as dengue and the anticipated rollout of a new tuberculosis vaccine by the end of the strategy cycle. These initiatives, alongside heightened pandemic preparedness following COVID-19 and other outbreaks, have reinforced the need for adjuvant-enhanced vaccines that enable rapid development and deployment.

The market also benefits from favorable regulatory support, including expedited approval pathways and targeted funding for critical vaccine technologies. However, challenges such as high development costs, stringent regulatory requirements, and the need for extensive clinical validation remain key barriers. Despite these constraints, the expanding pipeline of adjuvant-based vaccines and growing global awareness of immunization's role in public health continue to position the vaccine adjuvants industry for sustained growth over the forecast period.

Global Vaccine Adjuvants Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaccine adjuvants market report based on type, application, administration, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Pathogen
  • Adjuvant emulsion
  • Particulate
  • Combination
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Infectious diseases
  • Cancer
  • Others
  • Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Intradermal
  • Intranasal
  • Intramuscular
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Application
    • 1.1.3. Administration
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Application outlook
    • 2.2.3. Administration outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Vaccine Adjuvants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Vaccine Adjuvants Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Vaccine Adjuvants: Type Estimates & Trend Analysis

  • 4.1. Vaccine Adjuvants Market: Key Takeaways
  • 4.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
  • 4.3. Pathogen
    • 4.3.1. Pathogen market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.4. Adjuvant emulsion
    • 4.4.1. Adjuvant emulsion market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5. Particulate
    • 4.5.1. Particulate market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6. Combination
    • 4.6.1. Combination market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Vaccine Adjuvants: Application Estimates & Trend Analysis

  • 5.1. Vaccine Adjuvants Market: Key Takeaways
  • 5.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
  • 5.3. Infectious diseases
    • 5.3.1. Infectious diseases market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Vaccine Adjuvants: Administration Estimates & Trend Analysis

  • 6.1. Vaccine Adjuvants Market: Key Takeaways
  • 6.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
  • 6.3. Oral
    • 6.3.1. Oral market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.4. Intradermal
    • 6.4.1. Intradermal market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.5. Intranasal
    • 6.5.1. Intranasal market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6. Intramuscular
    • 6.6.1. Intramuscular market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Vaccine Adjuvants Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Vaccine Adjuvants Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.4.6. Denmark
      • 7.4.6.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.4.8. Norway
      • 7.4.8.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. GlaxoSmithKline plc
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Novartis/CSL Limited
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Agenus Inc
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Adjuvance Technologies, Inc
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Novavax Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. SPI Pharma
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Invivogen
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Avanti Polar Lipids
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Brentagg
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Vaccine Adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 3 North America vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 4 North America vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 5 North America vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
  • Table 6 U.S. vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 7 U.S. vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 8 U.S. vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 9 Canada vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 10 Canada vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 11 Canada vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 12 Mexico vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 13 Mexico vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 14 Mexico vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 15 Europe vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 16 Europe vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 17 Europe vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 18 Europe vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
  • Table 19 Germany vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 20 Germany vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 21 Germany vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 22 UK vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 23 UK vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 24 UK vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 25 France vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 26 France vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 27 France vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 28 Italy vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 29 Italy vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 30 Italy vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 31 Spain vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 32 Spain vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 33 Spain vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 34 Denmark vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 35 Denmark vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 36 Denmark vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 37 Sweden vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 38 Sweden vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 39 Sweden vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 40 Norway vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 41 Norway vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 42 Norway vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
  • Table 47 Japan vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 48 Japan vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 49 Japan vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 50 China vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 51 China vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 52 China vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 53 India vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 54 India vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 55 India vaccine adjuvants market, by administration, (USD Million) 2021 - 2033
  • Table 56 Australia vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 57 Australia vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 58 Australia vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 59 Thailand vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 60 Thailand vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 61 Thailand vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 62 South Korea vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 63 South Korea vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 64 South Korea vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 65 Latin America vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 66 Latin America vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 67 Latin America vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 68 Latin America vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
  • Table 69 Brazil vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 70 Brazil vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 71 Brazil vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 72 Argentina vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 73 Argentina vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 74 Argentina vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 75 Middle East and Africa vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 76 Middle East and Africa vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 77 Middle East and Africa vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 78 Middle East and Africa vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
  • Table 79 South Africa vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 80 South Africa vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 81 South Africa vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 85 UAE vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 86 UAE vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 87 UAE vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
  • Table 88 Kuwait vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
  • Table 89 Kuwait vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
  • Table 90 Kuwait vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Vaccine adjuvants: Market outlook
  • Fig. 8 Vaccine adjuvants: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Industry value chain analysis
  • Fig. 13 Vaccine adjuvants market driver impact
  • Fig. 14 Vaccine adjuvants market restraint impact
  • Fig. 15 Vaccine adjuvants market strategic initiatives analysis
  • Fig. 16 Vaccine adjuvants market: Type movement analysis
  • Fig. 17 Vaccine adjuvants market: Type outlook and key takeaways
  • Fig. 18 Pathogen market estimates and forecasts, 2021 - 2033
  • Fig. 19 Adjuvant emulsion market estimates and forecasts, 2021 - 2033
  • Fig. 20 Particulate market estimates and forecasts, 2021 - 2033
  • Fig. 21 Combination market estimates and forecasts, 2021 - 2033
  • Fig. 22 Others market estimates and forecasts, 2021 - 2033
  • Fig. 23 Vaccine adjuvants market: Application movement analysis
  • Fig. 24 Vaccine adjuvants market: Application outlook and key takeaways
  • Fig. 25 Infectious diseases market estimates and forecasts, 2021 - 2033
  • Fig. 26 Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 27 Others market estimates and forecasts, 2021 - 2033
  • Fig. 28 Vaccine adjuvants market: Administration movement analysis
  • Fig. 29 Vaccine adjuvants market: Administration outlook and key takeaways
  • Fig. 30 Oral market estimates and forecasts, 2021 - 2033
  • Fig. 31 Intradermal market estimates and forecasts, 2021 - 2033
  • Fig. 32 Intranasal market estimates and forecasts, 2021 - 2033
  • Fig. 33 Intramuscular market estimates and forecasts, 2021 - 2033
  • Fig. 34 Others market estimates and forecasts, 2021 - 2033
  • Fig. 35 Global vaccine adjuvants market: Regional movement analysis
  • Fig. 36 Global vaccine adjuvants market: Regional outlook and key takeaways
  • Fig. 37 North America market estimates and forecasts, 2021 - 2033
  • Fig. 38 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 39 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 40 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 41 Europe. market estimates and forecasts, 2021 - 2033
  • Fig. 42 UK market estimates and forecasts, 2021 - 2033
  • Fig. 43 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 44 France market estimates and forecasts, 2021 - 2033
  • Fig. 45 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 46 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 47 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 48 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 49 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 50 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 51 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 52 China market estimates and forecasts, 2021 - 2033
  • Fig. 53 India market estimates and forecasts, 2021 - 2033
  • Fig. 54 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 55 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 56 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 57 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 58 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 59 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 60 Middle East and Africa. market estimates and forecasts, 2021 - 2033
  • Fig. 61 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 62 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 63 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 64 Kuwait market estimates and forecasts, 2021 - 2033